Apogee Therapeutics Stock (NASDAQ:APGE), Analyst Ratings, Price Targets, Predictions

The latest price target for Apogee Therapeutics (NASDAQ: APGE) was reported by B of A Securities on May 10, 2024. The analyst firm set a price target for $80.00 expecting APGE to rise to within 12 months (a possible 51.17% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for Apogee Therapeutics (NASDAQ: APGE) was provided by B of A Securities, and Apogee Therapeutics initiated their buy rating.

There is no last upgrade for Apogee Therapeutics.

There is no last downgrade for Apogee Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apogee Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apogee Therapeutics was filed on May 10, 2024 so you should expect the next rating to be made available sometime around May 10, 2025.

While ratings are subjective and will change, the latest Apogee Therapeutics (APGE) rating was a initiated with a price target of $0.00 to $80.00. The current price Apogee Therapeutics (APGE) is trading at is $52.92, which is within the analyst’s predicted range.